Ginkgo Bioworks (NYSE:DNA) versus MindWalk (NASDAQ:HYFT) Head-To-Head Comparison

MindWalk (NASDAQ:HYFT) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Institutional & Insider Ownership

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 6.8% of MindWalk shares are owned by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares MindWalk and Ginkgo Bioworks”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$11.24 million	6.21	-$10.11 million	($0.26)	-5.75
Ginkgo Bioworks	$170.15 million	5.13	-$312.76 million	($5.01)	-2.58

MindWalk has higher earnings, but lower revenue than Ginkgo Bioworks. MindWalk is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for MindWalk and Ginkgo Bioworks, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	2	1	2.60
Ginkgo Bioworks	2	2	0	0	1.50

MindWalk presently has a consensus target price of $5.00, indicating a potential upside of 234.45%. Ginkgo Bioworks has a consensus target price of $6.33, indicating a potential downside of 51.09%. Given MindWalk’s stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than Ginkgo Bioworks.

Profitability

This table compares MindWalk and Ginkgo Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-105.11%	-133.26%	-77.78%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Volatility & Risk

MindWalk has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.

Summary

MindWalk beats Ginkgo Bioworks on 8 of the 15 factors compared between the two stocks.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.